STK11 and non-small cell lung carcinoma: Previous studies have indicated that co-occurring KRAS and STK11 mutations can lead to worse prognosis in NSCLC patients [59], and a recent study using G12C inhibitor sotorasib found that 50% of patients with co-occurring STK11 responded to KRAS inhibition, however those findings were non-significant and hypothesis-forming [60].